Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

(2021) Mehmet Kemal Samur et al.   Nature Communications

Integrative pathway enrichment analysis of multivariate omics data

(2020) Marta Paczkowska et al.   Nature Communications

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1

(2020) Anna Huo-Chang Mei et al.   Oncotarget

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma

(2020) Nandakumar Packiriswamy et al.   LEUKEMIA

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

(2020) Carolane Seiller et al.   Cell Death & Disease

Timing the initiation of multiple myeloma

(2020) Even H. Rustad et al.   Nature Communications

Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?

(2020) Shengli Xu et al.   Cancers

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

(2020) Mehmet Kemal Samur et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

(2020) Nadine Abdallah et al.   Blood Advances

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis

(2020) Normann Steiner et al.   Cancers

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

(2019) Esperanza M Algarín et al.   HAEMATOLOGICA

Relapsed refractory multiple myeloma: a comprehensive overview

(2019) Abdul Hamid Bazarbachi et al.   LEUKEMIA

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

(2019) Jeffrey R. Sawyer et al.   Blood Cancer Journal

Recent advance in the development of novel, selective and potent FGFR inhibitors

(2019) Feng-Tao Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

(2019) Francesco Maura et al.   Nature Communications

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

(2019) Timothy M. Schmidt et al.   Blood Cancer Journal

Daratumumab in high‐risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome

(2019) Meera Mohan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

(2018) Brian A. Walker et al.   BLOOD

MAGE-A antigens as targets for cancer immunotherapy

(2018) Erik Schooten et al.   CANCER TREATMENT REVIEWS

Patient Similarity Networks for Precision Medicine

(2018) Shraddha Pai et al.   JOURNAL OF MOLECULAR BIOLOGY

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

(2018) Niccolo Bolli et al.   LEUKEMIA

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis

(2018) Sean P. Pitroda et al.   Nature Communications

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

(2017) A Laganà et al.   LEUKEMIA

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

(2017) V Shah et al.   LEUKEMIA

Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells

(2017) Robin M Meyers et al.   NATURE GENETICS

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

(2017) Malachi Griffith et al.   NATURE GENETICS

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

(2016) E. A. Punnoose et al.   MOLECULAR CANCER THERAPEUTICS

A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway

(2016) Zubin Zhang et al.   Oncotarget

Smoldering multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

(2014) J. R. Sawyer et al.   BLOOD

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Similarity network fusion for aggregating data types on a genomic scale

(2014) Bo Wang et al.   NATURE METHODS

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

Breast Tumors with Elevated Expression of 1q Candidate Genes Confer Poor Clinical Outcome and Sensitivity to Ras/PI3K Inhibition

(2013) Muthulakshmi Muthuswami et al.   PLoS One

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

(2012) Wanjuan Yang et al.   NUCLEIC ACIDS RESEARCH

Integrative Subtype Discovery in Glioblastoma Using iCluster

(2012) Ronglai Shen et al.   PLoS One

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma

(2010) Leilei Chen et al.   ACTA PHARMACOLOGICA SINICA

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

(2010) C. M. Annunziata et al.   BLOOD

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

(2010) A. Broyl et al.   BLOOD

Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia*

(2010) Vesna Najfeld et al.   BRITISH JOURNAL OF HAEMATOLOGY

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS